
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


LMF Acquisition Opportunities Inc (ICU)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ICU (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $2
1 Year Target Price $2
0 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -26.68% | Avg. Invested days 17 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 23.62M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 1 | Beta -1.02 | 52 Weeks Range 0.31 - 5.79 | Updated Date 08/29/2025 |
52 Weeks Range 0.31 - 5.79 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.85 |
Earnings Date
Report Date 2025-08-13 | When - | Estimate -0.4 | Actual -0.18 |
Profitability
Profit Margin - | Operating Margin (TTM) -519.53% |
Management Effectiveness
Return on Assets (TTM) -156.15% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 18682748 | Price to Sales(TTM) 30.83 |
Enterprise Value 18682748 | Price to Sales(TTM) 30.83 | ||
Enterprise Value to Revenue 24.39 | Enterprise Value to EBITDA -8.13 | Shares Outstanding 27914600 | Shares Floating 27684021 |
Shares Outstanding 27914600 | Shares Floating 27684021 | ||
Percent Insiders 0.83 | Percent Institutions 6.98 |
Upturn AI SWOT
LMF Acquisition Opportunities Inc

Company Overview
History and Background
LMF Acquisition Opportunities Inc (LMAO) is a blank check company, also known as a special purpose acquisition company (SPAC). It was formed to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. SPACs typically have a limited lifespan to find and complete an acquisition.
Core Business Areas
- SPAC Formation: LMAO's core function is to raise capital through an initial public offering (IPO) with the intention of acquiring a private company and bringing it public. It focuses on deal sourcing, due diligence, and deal execution.
Leadership and Structure
SPACs are typically led by experienced investors or industry executives. The specific leadership structure can vary, but generally includes a CEO, CFO, and a board of directors. Details about LMAO's specific leadership team would be available in their SEC filings. After merger, the leadership team of the target company usually takes over.
Top Products and Market Share
Key Offerings
- SPAC IPO: The primary offering is the SPAC's IPO, which allows investors to buy units consisting of shares of common stock and warrants. The funds raised are held in a trust account and used to fund the acquisition of a target company. Market share is not applicable in the same way as a traditional company, but success can be measured by the size of the IPO raised and the quality of the acquisition target identified. Competitors include other SPACs seeking acquisition targets in similar industries.
Market Dynamics
Industry Overview
The SPAC market fluctuates based on investor sentiment, regulatory changes, and overall economic conditions. It can be a volatile market with periods of high activity followed by slowdowns. The industry is driven by private companies seeking an alternative to traditional IPOs and investors looking for potentially high-growth opportunities.
Positioning
LMAO's positioning depends on the industry it targets for acquisition and the experience of its management team. A strong management team and a promising target industry can give a SPAC a competitive advantage. The number of similar SPACS makes finding the right target difficult.
Total Addressable Market (TAM)
The TAM is the overall value of the private companies that are potential acquisition targets for SPACs. LMAO's position within this TAM depends on its specific focus and acquisition strategy. The total market value can be in the billions of dollars. LMAO is positioned as a facilitator for private companies to go public, therefore its position depends on market conditions for SPACs and the ability to find a suitable merger.
Upturn SWOT Analysis
Strengths
- Access to capital through IPO
- Experienced management team (potentially)
- Flexibility to target a wide range of industries
Weaknesses
- Limited lifespan to complete an acquisition
- Dilution to existing shareholders if warrants are exercised
- Dependence on finding a suitable acquisition target
- Market volatility affecting SPAC valuations
Opportunities
- Acquire a high-growth private company
- Generate significant returns for investors
- Benefit from favorable market conditions for SPACs
Threats
- Failure to find a suitable acquisition target
- Regulatory changes impacting SPACs
- Increased competition from other SPACs
- Market downturn negatively affecting the acquired company's performance
Competitors and Market Share
Key Competitors
Competitive Landscape
LMAO's competitive landscape is shaped by other SPACs seeking attractive acquisition targets. The advantage is the management team's experience and the sector the SPAC focuses on.
Growth Trajectory and Initiatives
Historical Growth: Growth is not applicable until an acquisition is completed.
Future Projections: Future projections depend on the success of the acquisition and the performance of the acquired company. Analysis will be speculative. The growth potential will exist in the target company acquired.
Recent Initiatives: Recent initiatives would include the search for and evaluation of potential acquisition targets.
Summary
LMF Acquisition Opportunities Inc is a SPAC designed to acquire a private company and take it public. Its success hinges on identifying and acquiring a suitable target within a limited timeframe. The company's future performance is entirely dependent on the quality and performance of the acquired entity. Investors should be aware of the risks associated with SPACs, including the potential for dilution and market volatility.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Financial News Outlets
- SPAC Data Providers
Disclaimers:
This analysis is based on publicly available information and is not financial advice. SPAC investments are speculative and carry a high degree of risk. All information must be confirmed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About LMF Acquisition Opportunities Inc
Exchange NASDAQ | Headquaters Denver, CO, United States | ||
IPO Launch date 2022-10-28 | CEO, Interim Chief Financial Officer, Principal Financial Officer, Treasurer & Executive Director Mr. Eric Schlorff | ||
Sector Healthcare | Industry Biotechnology | Full time employees 19 | Website https://seastarmedical.com |
Full time employees 19 | Website https://seastarmedical.com |
SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.